학술논문
665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S468-S468
Subject
Language
ISSN
0923-7534